NCT07158411

Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) Inhibition in Healthy Male Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Deciphera Pharmaceuticals, LLC · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants. This study will also assess the safety and tolerability when vimseltinib is co-administered with the clinical OCT2 substrate (metformin) in healthy male participants. This study will last approximately 25 days.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	Vimseltinib	Administered orally
DRUG	Metformin	Administered orally

Timeline

• Start date: 2025-11-20
• Primary completion: 2026-01-30
• Completion: 2026-01-30
• First posted: 2025-09-05
• Last updated: 2026-02-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study